Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9232122 | 0.87 | OPRM1 (0.58) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL5242605 | 0.85 | OPRM1 (0.60) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL15461526 | 0.83 | CYP2D6 (0.59) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL12581100 | 0.83 | OPRM1 (0.51) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL17140513 | 0.82 | OPRM1 (0.53) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL22770550 | 0.82 | OPRM1 (0.53) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL2985757 | 0.81 | SMN1; SMN2 (0.75) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL5674636 | 0.80 | OPRM1 (0.53) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL5671764 | 0.79 | OPRM1 (0.50) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL8894220 | 0.79 | CTSS (0.52) | OPRM1SMN1; SMN2CYP3A4HSD17B10SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114090948-A | Twiddle factor determination method and device, electronic equipment and storage medium | 哲库科技(北京)有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| CN-100478343-C | Purine compound and use as cannabinoid receptor ligands | PFIZER (US) | 2009-04-15 | — | — | CN | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| CN-100439369-C | Purine compounds and their use as cannabinoid receptor ligands | PFIZER (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080097097-A1 | Process for Preparing Purine Compounds | RAGAN JOHN A | 2008-04-24 | — | — | US | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | OPRM1 6/4885SMN1; SMN2 3678/4885CYP3A4 1886/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | OPRM1 6/4885SMN1; SMN2 3678/4885CYP3A4 1886/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | OPRM1 6/4885SMN1; SMN2 3678/4885CYP3A4 1886/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | OPRM1 79/4885SMN1; SMN2 4351/4885CYP3A4 383/4885 |
| US-20080097097-A1 | Process for Preparing Purine Compounds | PNP, UMPS, HPRT1 | OPRM1 1622/4885SMN1; SMN2 1231/4885CYP3A4 102/4885 |
| US-20040092520-A1 | Purine compounds and uses thereof | CNR1, CNR2, P2RY1 | OPRM1 28/4885SMN1; SMN2 2962/4885CYP3A4 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.